Selling, General, and Administrative Costs: Grifols, S.A. vs Galapagos NV

A Comparative Analysis of SG&A Expenses: Grifols, S.A. vs Galapagos NV

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Grifols, S.A. and Galapagos NV from 2014 to 2023. Over this period, Grifols, S.A. consistently outpaced Galapagos NV in SG&A spending, with expenses peaking at approximately €1.25 billion in 2023, marking a 90% increase from 2014. In contrast, Galapagos NV's SG&A expenses saw a more volatile trajectory, with a significant surge in 2022, reaching around €239 million, before dropping to €94 million in 2023. This fluctuation highlights the differing strategic priorities and market challenges faced by these companies. As Grifols, S.A. continues to expand its global footprint, its steady increase in SG&A expenses reflects its commitment to maintaining a competitive edge.